Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

NCT04059887 ·Status: COMPLETED ·Phase: PHASE4

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

NCT06890182 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

NCT05246514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

NCT05514132 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

NCT05465343 ·Status: COMPLETED ·Phase: PHASE2

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

NCT06812871 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT01203917 ·Status: COMPLETED ·Phase: PHASE4

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

NCT03118817 ·Status: COMPLETED ·Phase: PHASE1

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

NCT00319800 ·Status: UNKNOWN ·Phase: PHASE2

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NCT03861156 ·Status: COMPLETED ·Phase: PHASE2

Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients

NCT03721289 ·Status: COMPLETED

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

NCT06117644 ·Status: NOT_YET_RECRUITING

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

NCT05456867 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

NCT04563871 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

NCT03321695 ·Status: COMPLETED

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

NCT06192849 ·Status: RECRUITING ·Phase: PHASE2

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

NCT06319950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

NCT03418532 ·Status: TERMINATED ·Phase: PHASE1

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

NCT02691767 ·Status: COMPLETED ·Phase: NA

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965 ·Status: RECRUITING ·Phase: NA

Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

NCT04560452 ·Status: COMPLETED

Phase II Iressa & Carbo/Gem in NSCLC

NCT00264498 ·Status: COMPLETED ·Phase: PHASE2

Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma

NCT00625352 ·Status: UNKNOWN ·Phase: PHASE2